• Je něco špatně v tomto záznamu ?

Functional Analyses of HNF1A-MODY Variants Refine the Interpretation of Identified Sequence Variants

J. Malikova, A. Kaci, P. Dusatkova, I. Aukrust, J. Torsvik, K. Vesela, PD. Kankova, PR. Njølstad, S. Pruhova, L. Bjørkhaug

. 2020 ; 105 (4) : . [pub] 20200401

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21012750

CONTEXT: While rare variants of the hepatocyte nuclear factor-1 alpha (HNF1A) gene can cause maturity-onset diabetes of the young (HNF1A-MODY), other variants can be risk factors for the development of type 2 diabetes. As has been suggested by the American College of Medical Genetics (ACMG) guidelines for variant interpretation, functional studies provide strong evidence to classify a variant as pathogenic. OBJECTIVE: We hypothesized that a functional evaluation can improve the interpretation of the HNF1A variants in our Czech MODY Registry. DESIGN, SETTINGS, AND PARTICIPANTS: We studied 17 HNF1A variants that were identified in 48 individuals (33 female/15 male) from 20 Czech families with diabetes, using bioinformatics in silico tools and functional protein analyses (transactivation, protein expression, DNA binding, and nuclear localization). RESULTS: Of the 17 variants, 12 variants (p.Lys120Glu, p.Gln130Glu, p.Arg131Pro, p.Leu139Pro, p.Met154Ile, p.Gln170Ter, p.Glu187SerfsTer40, p.Phe215SerfsTer18, p.Gly253Arg, p.Leu383ArgfsTer3, p.Gly437Val, and p.Thr563HisfsTer85) exhibited significantly reduced transcriptional activity or DNA binding (< 40%) and were classified as (likely) pathogenic, 2/17 variants were (likely) benign and 3/17 remained of uncertain significance. Functional analyses allowed for the reclassification of 10/17 variants (59%). Diabetes treatment was improved in 20/29 (69%) carriers of (likely) pathogenic HNF1A variants. CONCLUSION: Functional evaluation of the HNF1A variants is necessary to better predict the pathogenic effects and to improve the diagnostic interpretation and treatment, particularly in cases where the cosegregation or family history data are not available or where the phenotype is more diverse and overlaps with other types of diabetes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012750
003      
CZ-PrNML
005      
20230712142015.0
007      
ta
008      
210420s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1210/clinem/dgaa051 $2 doi
035    __
$a (PubMed)32017842
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Křenek Malíková, Jana $u Department of Pediatrics, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic $7 xx0158263
245    10
$a Functional Analyses of HNF1A-MODY Variants Refine the Interpretation of Identified Sequence Variants / $c J. Malikova, A. Kaci, P. Dusatkova, I. Aukrust, J. Torsvik, K. Vesela, PD. Kankova, PR. Njølstad, S. Pruhova, L. Bjørkhaug
520    9_
$a CONTEXT: While rare variants of the hepatocyte nuclear factor-1 alpha (HNF1A) gene can cause maturity-onset diabetes of the young (HNF1A-MODY), other variants can be risk factors for the development of type 2 diabetes. As has been suggested by the American College of Medical Genetics (ACMG) guidelines for variant interpretation, functional studies provide strong evidence to classify a variant as pathogenic. OBJECTIVE: We hypothesized that a functional evaluation can improve the interpretation of the HNF1A variants in our Czech MODY Registry. DESIGN, SETTINGS, AND PARTICIPANTS: We studied 17 HNF1A variants that were identified in 48 individuals (33 female/15 male) from 20 Czech families with diabetes, using bioinformatics in silico tools and functional protein analyses (transactivation, protein expression, DNA binding, and nuclear localization). RESULTS: Of the 17 variants, 12 variants (p.Lys120Glu, p.Gln130Glu, p.Arg131Pro, p.Leu139Pro, p.Met154Ile, p.Gln170Ter, p.Glu187SerfsTer40, p.Phe215SerfsTer18, p.Gly253Arg, p.Leu383ArgfsTer3, p.Gly437Val, and p.Thr563HisfsTer85) exhibited significantly reduced transcriptional activity or DNA binding (< 40%) and were classified as (likely) pathogenic, 2/17 variants were (likely) benign and 3/17 remained of uncertain significance. Functional analyses allowed for the reclassification of 10/17 variants (59%). Diabetes treatment was improved in 20/29 (69%) carriers of (likely) pathogenic HNF1A variants. CONCLUSION: Functional evaluation of the HNF1A variants is necessary to better predict the pathogenic effects and to improve the diagnostic interpretation and treatment, particularly in cases where the cosegregation or family history data are not available or where the phenotype is more diverse and overlaps with other types of diabetes.
650    _2
$a dospělí $7 D000328
650    _2
$a biologické markery $x analýza $7 D015415
650    _2
$a diabetes mellitus 1. typu $x genetika $x metabolismus $x patologie $7 D003922
650    _2
$a diabetes mellitus 2. typu $x genetika $x metabolismus $x patologie $7 D003924
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a hepatocytární jaderný faktor 1-alfa $x genetika $7 D051538
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a mutace $7 D009154
650    _2
$a fenotyp $7 D010641
650    _2
$a prognóza $7 D011379
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kaci, Alba $u KG Jebsen Center for Diabetes Research, Department of Clinical Science, Bergen, Norway ; Department of Pediatrics and Adolescents, Haukeland University Hospital, Bergen, Norway
700    1_
$a Dusatkova, Petra $u Department of Pediatrics, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
700    1_
$a Aukrust, Ingvild $u KG Jebsen Center for Diabetes Research, Department of Clinical Science, Bergen, Norway ; Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway
700    1_
$a Torsvik, Janniche $u KG Jebsen Center for Diabetes Research, Department of Clinical Science, Bergen, Norway ; Department of Pediatrics and Adolescents, Haukeland University Hospital, Bergen, Norway
700    1_
$a Vesela, Klara $u Department of Pediatrics, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
700    1_
$a Kankova, Pavla Dvorakova $u Department of Pediatrics, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
700    1_
$a Njølstad, Pål R $u KG Jebsen Center for Diabetes Research, Department of Clinical Science, Bergen, Norway ; Department of Pediatrics and Adolescents, Haukeland University Hospital, Bergen, Norway
700    1_
$a Pruhova, Stepanka $u Department of Pediatrics, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
700    1_
$a Bjørkhaug, Lise $u Department of Safety, Chemistry and Biomedical Laboratory Sciences, Western Norway University of Applied Sciences, Bergen, Norway
773    0_
$w MED00002582 $t The Journal of clinical endocrinology and metabolism $x 1945-7197 $g Roč. 105, č. 4 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32017842 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20230712142016 $b ABA008
999    __
$a ok $b bmc $g 1651002 $s 1133129
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 105 $c 4 $e 20200401 $i 1945-7197 $m The Journal of clinical endocrinology and metabolism $n J Clin Endocrinol Metab $x MED00002582
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace